All In Biotech

Drug Trial Radar · NCT02859948

A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SKLB1028 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia

Last checked: Nov 19, 2026Latest source record: Aug 9, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

18

Planned (sponsor's estimate)

Start

May 2016

Primary completion

Dec 2017

Study completion Jan 2018

Sponsor

Sponsor type
Industry
First posted
Aug 9, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients will receive oral SKLB1028 for 28 days to study the side effects, tolerability and best dose for treating relapsed or refractory acute myeloid leukemia With FLT3 Mutations.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • SKLB1028Drug

    SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Incidence of dose limiting toxicity (DLT)and Adverse Event (AE)Time frame: 28 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital,Sichuan University

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.